Antegenes

🎗𝗣𝗿𝗼𝘀𝘁𝗮𝘁𝗲 𝗖𝗮𝗻𝗰𝗲𝗿 𝗦𝗰𝗿𝗲𝗲𝗻𝗶𝗻𝗴: 𝗔 𝗠𝗼𝗿𝗲 𝗣𝗲𝗿𝘀𝗼𝗻𝗮𝗹 𝗔𝗽𝗽𝗿𝗼𝗮𝗰𝗵   Following Sir Chris Hoy’s recent heartfelt testimony, the conversation on prostate cancer screening has rightly intensified. In the UK, approximately 52,000 men are diagnosed each year, and early detection is key to improving outcomes.   PSA testing is accessible to those who request it, but it doesn’t always give a full picture. MRI scans would be ideal but are simply too resource-intensive for routine use.   This is where a 𝘁𝗮𝗶𝗹𝗼𝗿𝗲𝗱, 𝗴𝗲𝗻𝗲𝘁𝗶𝗰 𝗿𝗶𝘀𝗸-𝗯𝗮𝘀𝗲𝗱 𝗮𝗽𝗽𝗿𝗼𝗮𝗰𝗵 could make a difference.   With recent UK research backing it, Polygenic Risk Score (PRS) testing offers men a clearer understanding of their genetic risk for prostate cancer. This personalised insight can help inform decisions around prevention and screening, such as PSA testing frequency and even suggest whether an MRI might be beneficial for high-risk individuals.   For those wanting to take a proactive step, PRS genetic testing with a personalised cancer prevention plan empowers men to make informed choices about their health based on their unique risk profile. Interested in learning more? The service is already available as home-based testing through our website: https://lnkd.in/dsdrmZXV   Or please get in touch with our UK partner Berkeley Genetics.

Exciting news! 🎉 We’re proud to announce that Antegenes has been selected as a semi-finalist in the EIT Health Catapult 2024-25! We look forward to showcasing our innovative approach to personalised cancer prevention alongside Europe's best and brightest in heathtech and life sciences. Congratulations to all our fellow semi-finalists – let's drive meaningful change in healthcare together! 🚀 Stay tuned for more updates as we move closer to the finals in April 2025! #healthtech #personalisedcancerprevention #catapult24

🎗 October marked Breast Cancer Awareness Month. Unfortunately, breast cancer is becoming the most common cancer globally, with incidence rates rising, including among younger women. However, the good news is that the likelihood of developing breast cancer can be reduced by considering risk factors, and, with timely detection, it can be successfully treated.   The month concluded with an important event – the 1st International Conference on Young Women’s Breast Cancer and Health in Lisbon. Representing Estonia, Prof. Neeme Tõnisson presented personalised breast cancer prevention, developed, researched, and implemented clinically by the EIT Health BRIGHT project in Estonia.   It was encouraging to see discussions at the conference, particularly from women’s and patient organisations, emphasising that for effective breast cancer prevention and timely detection, women need to understand their personal risk levels, and healthcare professionals must provide personalised prevention guidelines based on this.   As an oncologist, I’m honoured to serve as a Global Ambassador of the Breast Cancer in Young Women Foundation (BCYWF) for such an important cause. Special thanks to Prof. Luis Costa, the Portuguese leader of the conference, and the entire team.

🏆 We are incredibly honoured to have been awarded the title of "Most Successful Medical and Life Sciences Entrepreneur" by the City of Tartu! As Antegenes was founded in Tartu, this recognition holds a special place in our hearts.   Success in the healthcare sector is often a long journey, and such recognition only strengthens our resolve to keep pushing forward. At Antegenes, we are pioneering personalised cancer prevention in healthcare. It is not just a new technology we are bringing to the market, but also an innovative model in healthcare based on individuals' genetic risk factors. Our work is to lead the way in modern cancer prevention in Estonia and across Europe. 🌍   We still have a long way to go before personalised prevention becomes a regular part of our healthcare systems, but we will get there and this year has seen significant progress.   A heartfelt thanks to our incredible team, partners, and early supporters across Europe. Thank you for being part of this journey — it's a true joy to work alongside you. 🙏   #Award #CancerPrevention #PersonalisedMedicine #HealthcareInnovation #Tartu #Teamwork

👉 Our UK Country Manager, Akshay Mody, recently participated in the Prevent Breast Cancer Research Conference in Manchester, UK. The event gathered clinicians and researchers worldwide for crucial discussions on breast cancer prediction and prevention. 💗The conference highlighted significant updates from breast cancer studies and how prediction can transform future diagnoses. Polygenic risk scores are central to prevention, enabling personalised prevention strategies and timely treatment for women at increased genetic risk. Thank you to the organisers and partners! Prevent Breast Cancer Berkeley Genetics 🎗️PS. It is October – International Breast Cancer Awareness Month, a time to focus on breast cancer and its prevention. Stay tuned! #BreastCancerAwareness #BreastCancerPrevention #PRS

📻 Oncologist, Dr Peeter Padrik, recently visited Estonia's national radio channel for an engaging discussion on the future of personalised medicine and its potential in cancer prevention. (This conversation was held in Estonian.) 🎧Soovitame põnevat kuulamist! Onkoloog dr Peeter Padrik käis külas Vikerraadio saates Huvitaja. Põneva vestluse teemaks oli personaalmeditsiini potentsiaal vähiennetuses. Kuula saadet ja saad teada, milliseid probleeme ennetav personaalmeditsiin lahendab ja mida selle rakendamiseks vaja on. 👉 Intervjuu algab saate 30. minutil. Kuula saadet siit: https://bit.ly/huvitaja

💙💪Men’s health matters. As Prostate Cancer Awareness Day often falls towards the end of September, it’s a timely reminder that prostate cancer is the most common malignancy in men. Let’s prioritise prevention. Swipe through to learn more about the risks and prevention. 👉 #MensHealth #ProstateCancerAwareness #CancerPrevention #HealthMatters #ProstateCancer #PersonalisedCancerPrevention

🌍 Patient involvement in shaping cancer prevention and treatment is a MUST. This week, our Business Development Manager Krista Kruuv-Käo was honoured to speak at a seminar organised by Tartu University Hospital. The event focused on including the patient's voice in healthcare. She shared the latest results from the BRIGHT study on personalised breast cancer prevention. Meeting breast cancer survivors in Portugal (EVITA - Cancro Hereditário), Sweden (The Swedish Breast Cancer Association), Norway (Brystkreftforeningen), and Estonia has truly inspired us. Your experiences motivate us to bring personalised breast cancer prevention into broader clinical use even faster! 💖 #PatientVoice #BreastCancerPrevention #BRIGHTStudy #PrecisionMedicine #Europe #HealthcareTransformation #HealthcareInnovation

Our BRIGHT consortium members presented groundbreaking clinical evidence on next-generation personalised breast cancer prevention at #ESMO24. Stay tuned🚀

This week, Antegenes was invited to present our innovative genetics-based cancer prevention services to the Norwegian e-health delegation. Our services, already in use across Europe, offer personalised cancer prevention powered by polygenic risk assessment and clinical recommendations, digitised for seamless use across borders. Our Business Development Manager Krista Kruuv-Käo, presented how, through successful collaborations such as our work in the AnteNOR consortium, we have gained valuable evidence for the clinical use of personalised breast cancer prevention in Norway. Looking ahead, we are committed to making these innovative solutions widely available in Norway and beyond. 🌍 She also shared insights about our progress in Estonia, where the country is set to launch the world’s first personalised genetic risk-based breast cancer screening for 40-year-old women in 2025, tailoring the start and frequency of mammograms based on individual genetic risk. 💗 Innovation is here, and it's already saving lives! 💪 Thank you to the organisers, Trade with Estonia, e-Estonia, EASi ja KredExi ühendasutus 🙌 #eHealth #CancerPrevention #PersonalisedMedicine #GeneticTesting #Innovation #Norway #BreastCancerAwareness #DigitalHealth #HealthTech #PolygenicRiskScore #Antegenes